2025-04-04 19:35:43
Latest Post
Sai Life Sciences sets up Peptide Research Center in India
Netweb Technologies Ltd receives PLI Incentive Under IT Hardware Scheme 2.0
BHEL signs contract for ± 800 kV, 6000 MW Bhadla-Fatehpur LCC HVDC Terminal Station along with AC Transmission at Bhadla and Fatehpur
DEE Development Engineers Limited receives order worth approx. Rs. 55 crores- SURATWWALA BUSINESS GROUP Ltd purchases new commercial office space
Stock Report
Astec LifeSciences Ltd consolidated Q2FY23 PAT rises to Rs. 18.30 crores
Posted On : 2022-10-28 16:50:21( TIMEZONE : IST )
Astec LifeSciences Limited has reported Consolidated financial results for the period ended September 30, 2022.
Financial Results (Q2 FY2023) - QoQ Comparison
The company has reported total income of Rs. 203.7329 crores during the period ended September 30, 2022 as compared to Rs. 186.9767 crores during the period ended June 30, 2022.
The company has posted net profit / (loss) of Rs. 18.3082 crores for the period ended September 30, 2022 as against net profit / (loss) of Rs. 11.3999 crores for the period ended June 30, 2022.
The company has reported EPS of Rs. 9.34 for the period ended September 30, 2022 as compared to Rs. 5.81 for the period ended June 30, 2022.
| Financials | Q2 FY2023 | Q1 FY2023 | % Change |
| Total Income | ₹203.7329 crs | ₹186.9767 crs |  8.96% |
| Net Profit | ₹18.3082 crs | ₹11.3999 crs | 60.60% |
| EPS | ₹9.34 | ₹5.81 | 60.76% |
Financial Results (Q2 FY2023) - YoY Comparison
The company has reported total income of Rs.203.7329 crores during the period ended September 30, 2022 as compared to Rs.103.4737 crores during the period ended September 30, 2021.
The company has posted net profit / (loss) of Rs.18.3082 crores for the period ended September 30, 2022 as against net profit / (loss) of Rs.9.0724 crores for the period ended September 30, 2021.
The company has reported EPS of Rs.9.34 for the period ended September 30, 2022 as compared to Rs.4.63 for the period ended September 30, 2021.
| Financials | Q2 FY2023 | Q2 FY2022 | % Change |
| Total Income | ₹203.7329 crs | ₹103.4737 crs | 96.89% |
| Net Profit | ₹18.3082 crs | ₹9.0724 crs | 101.80% |
| EPS | ₹9.34 | ₹4.63 | 101.73% |
Financial Results (Half Year Ended FY2023) - YoY Comparison
The company has reported total income of Rs.390.7096 crores during the 6 Months period ended September 30, 2022 as compared to Rs.232.9341 crores during the 6 Months period ended September 30, 2021.
The company has posted net profit / (loss) of Rs.29.7081 crores for the 6 Months period ended September 30, 2022 as against net profit / (loss) of Rs.22.0572 crores for the 6 Months period ended September 30, 2021.
The company has reported EPS of Rs.15.15 for the 6 Months period ended September 30, 2022 as compared to Rs.11.25 for the 6 Months period ended September 30, 2021.
| Financials | Half Year Ended FY2023 | Half Year Ended FY2022 | % Change |
| Total Income | ₹390.7096 crs | ₹232.9341 crs | 67.73% |
| Net Profit | ₹29.7081 crs | ₹22.0572 crs | 34.69% |
| EPS | ₹15.15 | ₹11.25 | 34.67% |
Shares of Astec LifeSciences Limited was last trading in BSE at Rs. 2184.45 as compared to the previous close of Rs. 2153.05. The total number of shares traded during the day was 2128 in over 625 trades.
The stock hit an intraday high of Rs. 2199.00 and intraday low of 2148.35. The net turnover during the day was Rs. 4636469.00.
